Patents by Inventor Albert Haertl

Albert Haertl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating infectious diseases with polysaccharide derivatives
    Patent number: 7297687
    Abstract: The present invention relates to a method of treating infectious diseases, that involves: (a) providing an alpha-glycosidically linked starch polysaccharide derivative; and (b) inhibiting the growth of an infectious disease by administering a composition comprising the alpha-glycosidically linked starch polysaccharide derivative. The alpha-glycosidically linked starch polysaccharide derivative represented by the following general formula I, in which: the alpha-glycosidically linked starch polysaccharide derivative has a degree of quaternary ammonium group substitution of from 0.4 to 2.
    Type: Grant
    Filed: January 10, 2003
    Date of Patent: November 20, 2007
    Assignee: Wolff Cellulosics GmbH Co. KG
    Inventors: Vera Haack, Thomas Heinze, Michaela Schmidtke, Ute Möllmann, Hans-Martin Dahse, Albert Härtl
  • Method for treating neurological conditions and inducing immunosuppression with cephaibols
    Patent number: 7041649
    Abstract: Embodiments of the present invention relate to administering cephaibols to treat conditions of the nervous system and to treat those conditions in which suppressing the immune system would have beneficial effect.
    Type: Grant
    Filed: May 21, 2003
    Date of Patent: May 9, 2006
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Mathias Schiell, Laszio Vertesy, Joachim Wink, Brigitte Schlegel, Albert Haertl, Udo Graefe
  • Method for treating neurological conditions and inducing immunosuppression with cephaibols
    Publication number: 20040023886
    Abstract: Embodiments of the present invention relate to administering cephaibols to treat conditions of the nervous system and to treat those conditions in which suppressing the immune system would have beneficial effect.
    Type: Application
    Filed: May 21, 2003
    Publication date: February 5, 2004
    Applicant: Aventis Pharma Deutschland Gmbh
    Inventors: Mathias Schiell, Laszio Vertesy, Joachim Wink, Brigitte Schlegel, Albert Haertl, Udo Graefe
  • Ergoline amine derivatives with blood pressure lowering effect
    Patent number: 6358967
    Abstract: The invention relates to novel derivatives of ergoline of the general formula 1 in which R1 together with the two adjacent N atoms is the residue of a diamine and R4 together with the two adjacent carbonyl groups is the residue of a dicarboxylic acid. R2, R3, R6, R7, R8 can be H or an organic radical. R7 and R8 are H or together are a bond. The compounds show a strong antihypertensive effect. These effects moreover occur after intravenous and enteral administration even at dosages in the region of a few &mgr;g/kg (body weight). The compounds can accordingly be used as pharmaceuticals for hypertensive diseases in human medicine.
    Type: Grant
    Filed: April 19, 2001
    Date of Patent: March 19, 2002
    Assignee: CyBio Screening GmbH
    Inventors: Ralf Wyrwa, Albert Haertl, Erika Glusa, Susanne Grabley, Ralf Thiericke